Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pelcitoclax in advanced neuroendocrine tumor
NCT04893759Phase 1Terminated
- Sponsor
- Ascentage Pharma
- Start
- Jan 2022
- Primary completion
- Sep 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pelcitoclax in Neuroendocrine Neoplasm (NEN), sponsored by Ascentage Pharma. Primary endpoints: Maximum tolerated dose at 28 days and Safety data at 24 months. Started Jan 2022; status: terminated.
02
Drugs
pelcitoclax
03
Conditions
Neuroendocrine Neoplasm (NEN)
Beyond the preview
Go deeper on NCT04893759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04893759.